Livtencity is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Livtencity's patents will be open to challenges from 23 November, 2025. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 04, 2032. Details of Livtencity's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11684632 | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Livtencity's patents.
Latest Legal Activities on Livtencity's Patents
Given below is the list of recent legal activities going on the following patents of Livtencity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 23 Feb, 2024 | US11684632 |
| Change in Power of Attorney (May Include Associate POA) Critical | 23 Feb, 2024 | US11684632 |
| Email Notification Critical | 14 Dec, 2023 | US11684632 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 13 Dec, 2023 | US11684632 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 13 Dec, 2023 | US11684632 |
| Adjustment of PTA Calculation by PTO | 12 Dec, 2023 | US11684632 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 12 Dec, 2023 | US11684632 |
| Pet Dec Routed to Certificate of Corrections Branch | 12 Dec, 2023 | US11684632 |
| Petition Entered | 23 Aug, 2023 | US11684632 |
| Email Notification Critical | 27 Jun, 2023 | US11684632 |
FDA has granted several exclusivities to Livtencity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Livtencity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Livtencity.
Exclusivity Information
Livtencity holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Livtencity's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
US patents provide insights into the exclusivity only within the United States, but Livtencity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Livtencity's family patents as well as insights into ongoing legal events on those patents.
Livtencity's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Livtencity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 04, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Livtencity Generics:
There are no approved generic versions for Livtencity as of now.
About Livtencity
Livtencity is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for treating post-transplant cytomegalovirus (CMV) infection/disease refractory to other antiviral treatments in stem cell, kidney, or liver transplant recipients. Livtencity uses Maribavir as an active ingredient. Livtencity was launched by Takeda Pharms Usa in 2021.
Approval Date:
Livtencity was approved by FDA for market use on 23 November, 2021.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Livtencity is 23 November, 2021, its NCE-1 date is estimated to be 23 November, 2025.
Active Ingredient:
Livtencity uses Maribavir as the active ingredient. Check out other Drugs and Companies using Maribavir ingredient
Treatment:
Livtencity is used for treating post-transplant cytomegalovirus (CMV) infection/disease refractory to other antiviral treatments in stem cell, kidney, or liver transplant recipients.
Dosage:
Livtencity is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | TABLET | Prescription | ORAL |